FLASH diagnostics brings cutting-edge microscopy developments to the clinical diagnosis of patients. Optical tissue clearing in combination with high-speed imaging will facilitate accurate diagnosis in sizeable intact tissue volumes. They employ three-dimensional screening to improve cancel diagnosis for more precise cancer patient staging.
The company is a spin-out from the Francis Crick Institute in London. Francis Crick Institute is a biomedical research institute established in partnership between Cancer Research UK, Imperial College London, King’s College London, The Medical Research Council UK, University College London and Wellcome Trust.
We had a chat with Axel Behrens, CEO of FLASH diagnostics, to get more acquainted with the company’s mission and vision. The founder team consists of Axel Behrens, Jorge Almagro and Hendrik Messal.
What is the key driver for FLASH diagnostics?
We hope our technology can help improve cancer diagnosis, thus improving the chances of successfully treating various types of cancer.
What would be the optimal outcome of the Venture Lab program?
The main objective is to develop our technology further and collaborate with potential partners, such as hospitals, patient organizations and manufacturers.
Who are your main competitors and how do you differ from them?
FLASH diagnostics uses proprietary patented technology that allows analysis of large tissues samples to improve cancer diagnosis. We are not aware of a competing technology with the same capabilities.
Tony Cheng-fu Chang, Senior Business Developer, says the following about FLASH diagnostics:
“FLASH diagnostics is developing a novel whole tissue visualization technology that enables the analysis of large cancer specimens e with unprecedented depth and precision to provide high confidence detection of cancer cell infiltration. We are excited and proud to support the team in their journey to bring a new paradigm to cancer diagnosis and cancer surgery care to the next level.”
Meet the start-ups: HEI Therapeutics